Abstract
Bacillus Calmette and Guérin (BCG) is a widely used live attenuated vaccine against tuberculosis (TB). However, its efficacy in preventing pulmonary TB in adults is limited and variable. Gene editing in BCG has enabled advances in the study of immune response evasion mechanisms and in the development of new vaccines. The CRISPR/Cas9 tool, with its great biotechnological potential, allows …